Document is current
Any future updates will be listed below
-
Authors
Teter, Olivia M. https://orcid.org/0000-0001-8490-2543
McQuade, Amanda https://orcid.org/0000-0001-5368-6788
Hagan, Venus
Liang, Weiwei https://orcid.org/0009-0000-0337-6896
Dräger, Nina M.
Sattler, Sydney M. https://orcid.org/0000-0002-5551-3378
Holmes, Brandon B. https://orcid.org/0000-0002-1153-840X
Castillo, Vincent Cele
Papakis, Vasileios
Leng, Kun
Boggess, Steven
Nowakowski, Tomasz J.
Wells, James https://orcid.org/0000-0001-8267-5519
Kampmann, Martin https://orcid.org/0000-0002-3819-7019
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01 MH115747, R01 MH125516)
National Science Foundation (2034836)
Alzheimer's Association (AARF-22-973222)
Larry L. Hillblom Foundation (2022-A-016-FEL)
- License Information
-
More Information
Article History
Received: 1 June 2024
Revised: 6 March 2025
Accepted: 26 March 2025
First Online: 6 April 2025
Competing interests
: MK is a co-scientific founder of Montara Therapeutics and serves on the Scientific Advisory Boards of Montara Therapeutics, Engine Biosciences, Casma Therapeutics, Alector, and Neurocrine, and is an advisor to Modulo Bio and Recursion Therapeutics. MK is an inventor on US Patent 11,254,933 related to CRISPRi and CRISPRa screening, and on a US Patent application on in vivo screening methods.
: All methods were performed in accordance with the relevant guidelines and regulations. Experiments with previous a previously derived WTC11 iPSC line were approved by the UCSF GESCR (Study number 19-28308). Informed consent was obtained from the human subject when the WTC11 was originally generated.
